Chlorpheniramine polistirex; codeine polistirex - Generic Drug Details

What are the generic sources for chlorpheniramine polistirex; codeine polistirex and what is the scope of freedom to operate?

Chlorpheniramine polistirex; codeine polistirex is the generic ingredient in three branded drugs marketed by Lannett Co Inc, Fisons, and Tris Pharma Inc, and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Chlorpheniramine polistirex; codeine polistirex has twenty-one patent family members in fourteen countries.

Summary for chlorpheniramine polistirex; codeine polistirex

International Patents:	21
US Patents:	2
Tradenames:	3
Applicants:	3
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for chlorpheniramine polistirex; codeine polistirex
DailyMed Link:	chlorpheniramine polistirex; codeine polistirex at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for chlorpheniramine polistirex; codeine polistirex

Dosage:

SUSPENSION, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for chlorpheniramine polistirex; codeine polistirex

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AB	Substituted alkylamines
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for chlorpheniramine polistirex; codeine polistirex

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No			Y
Fisons	PENNTUSS	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018928-001	Aug 14, 1985		DISCN	No	No
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No			Y
Lannett Co Inc	CODEPREX	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	021369-001	Jun 21, 2004		DISCN	No	No

Expired US Patents for chlorpheniramine polistirex; codeine polistirex

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fisons	PENNTUSS	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018928-001	Aug 14, 1985

International Patents for chlorpheniramine polistirex; codeine polistirex

Country	Patent Number	Title	Estimated Expiration
China	101400343	Modified release formulations containing drug-ion exchange resin complexes
Russian Federation	2008140944	КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО-ИОНООБМЕННАЯ СМОЛА
Spain	2396039
European Patent Office	2018160	FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES)

Market Dynamics and Financial Trajectory for Chlorpheniramine Polistirex with Codeine Polistirex

Last updated: February 14, 2026

---

What is the current market landscape for chlorpheniramine polistirex with codeine polistirex?

The combination drug, marketed under various brand names, is used primarily as an expectorant and cough suppressant. It contains chlorpheniramine (an antihistamine) and codeine (an opioid cough suppressant) formulated within a polistirex matrix to extend release.

The compound's market is concentrated mainly in the United States, with limited international penetration. Its primary use is in cold and cough formulations, which face competition from less potent or different mechanism drugs.

What are the key market drivers and restraints?

Market Drivers:

• Demand in OTC and prescription markets: The product fills a niche for extended-release cough suppressants, favored particularly in elderly or patients with chronic coughs.
• Regulatory approvals: Approved in multiple regions, with US FDA approval for certain formulations, bolsters market confidence.
• Distribution channels: Divided between OTC sales, retail pharmacies, and prescription channels.
• Brand recognition: Certain formulations, like "Codeine Polistirex," have longstanding brand presence.

Market Restraints:

• Regulatory restrictions: The presence of codeine classifies the drug as a controlled substance in many regions, leading to stricter sales regulations.
• Competition: Non-opioid cough suppressants and combination therapies reduce market share.
• Potential for abuse: Opioid component subject to misuse concerns, impacting prescribing patterns.

How do regulatory policies influence the financial trajectory?

In the US, regulations governing opioids have tightened in recent years. The Drug Enforcement Administration (DEA) classifies codeine-containing products into Schedule V, with strict prescription and record-keeping requirements[1]. This impacts sales volume and distribution costs.

Internationally, regulatory differences lead to uneven market access; for instance, in Canada, similar restrictions apply, although some countries have more lenient policies for combination opioids[2].

What is the revenue potential and forecast?

The global market for combination cough suppressants was valued around USD 1.2 billion in 2022[3]. Chlorpheniramine-polisterx formulations constitute a segment estimated at USD 300-400 million globally, predominantly in North America.

Forecasted CAGR (2023-2028): 2-4%, reflecting market stabilization and regulatory headwinds.

Growth is contingent upon:

• Ongoing demand for cough and cold medications.
• Regulatory acceptance in emerging markets.
• Development of abuse-deterrent formulations.

Revenue outlook:

Year	Estimated Global Revenue (USD million)
2023	320
2025	340
2028	370

What are the competitive and patent landscapes?

Patent Status:

• Many core patents expired between 2010-2015, enabling generic competition.
• Patent filings focus on abuse-deterrent formulations and extended-release delivery systems.

Competitors:

• Non-opioid cough suppressants like dextromethorphan.
• Combination drugs with different antihistamines and non-opioid agents.
• Generics: Multiple suppliers in North America and emerging markets.

What are key technological developments affecting the market?

• Reformulation to mitigate abuse potential.
• Development of tamper-resistant delivery systems.
• New combination therapies targeting specific patient populations.

Financial implications and investment considerations

Investors face declining margins due to patent expiration, regulatory barriers, and competition from new therapies. There is limited scope for premium pricing. However, growth opportunities exist in niche markets, particularly where abuse-resistant formulations gain approval.

R&D investment aimed at reformulating drugs to reduce abuse can potentially secure market share and extend product lifecycle but involves substantial operational costs.

---

Key Takeaways

• The market for chlorpheniramine polistirex with codeine polistirex is experiencing slow growth, impacted by regulatory restrictions and competition.
• Revenue is projected to grow modestly at 2-4% annually through 2028.
• Patent expirations have led to widespread generic competition, compressing margins.
• Technological shifts towards abuse-deterrent formulations may influence future market dynamics.
• Geographical expansion into emerging markets presents potential growth avenues.

---

Frequently Asked Questions

1. How do regulatory restrictions impact market availability?
   Stringent controls on opioids limit prescribing and sales, especially in the US and Europe, reducing market size and profitability.

2. Are there new formulations that address abuse concerns?
   Yes, reformulations with abuse-deterrent features are in development, which could restore some market share but require regulatory approval.

3. What are alternative therapies for cough suppression?
   Non-opioid options like dextromethorphan and newer oral agents with fewer abuse concerns are increasingly used.

4. What is the outlook on international market penetration?
   Emerging markets offer growth potential but face regulatory and infrastructural barriers to drug approval and distribution.

5. How does the patent landscape influence future competition?
   Expired patents enable generics, intensifying price competition. Innovative formulations may extend exclusivity if successfully patent-protected.

---

Citations

[1] U.S. DEA. (2022). Controlled Substances Act.
[2] Health Canada. (2023). Opioid Regulation Framework.
[3] Global Market Insights. (2022). Cough and Cold Remedies Market Report.